Guiding light
12 January 2006

J&J’s bid isn’t just lower than Boston Scientific’s $25bn rival offer. It hasn’t even increased it to the level that it originally offered. What’s more, the J&J offer is below Guidant’s share price. Guidant’s recommendation is puzzling.